Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours

Exclusion Criteria

• •1. Any adverse event from prior anti-tumour therapy has not yet recovered to ≤grade 1 of CTCAE v5.0
• •2. Uncontrolled tumour-related pain
• •3. Known central nervous system (CNS)
• •4. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures
• •5. Use of inhaled corticosteroids
• •6. Known history of autoimmune disease
• •7. Use of any live attenuated vaccines within 28 days
• •8. Have severe cardiovascular disease
• •9. Uncontrolled or severe illness
• •10. History of immunodeficiency disease
• •11. Active malignancies which are likely to require the treatment.
• •12. Child-bearing potential female
• •13. Have psychiatric illness or disorders